Monographie - Amikacin sulfate

Laatste update :
19/11/2024

Amikacin sulfate

Molecuulstructuur

Merknamen in verschillende landen

Handelsnamen zijn slechts een indicatie; de samenstelling van hulpstoffen kan per land variëren afhankelijk van de fabrikant

Adnet	Indië
Agnicin	Mexico
Akamin	Ecuador
Akim	Ecuador
Amicacil	Brazilië
Amicilon	Brazilië
Amicin	Maleisië
Amicip	Venezuela
Amijeksin	Turkije
Amikabiot	Ecuador, Peru
Amikacin	Canada, Duitsland, Egypte, Groot Britannië, Iran, Maleisië, nieuw Zeeland, Saudi-Arabië, USA
Amikacina	Argentinië, Chili, Colombia, Ecuador, Italië, Mexico, Peru, Spanje, Venezuela
Amikacine	België, Frankrijk, Marokko, Nederland
Amikafur	Mexico
Amikagram	Peru
Amikalem	Mexico
Amikamed	Peru
Amikamek	Peru
Amikan	Italië
Amikavax	Venezuela
Amikaver	Turkije
Amikayect	Mexico
Amikem	Peru
Amiketem	Turkije
Amikin	Australië, Brazilië, Colombia, Ecuador, Egypte, Groot Britannië, Hongarije, Ierland, Mexico, Peru, Polen, Saudi-Arabië, Tunisie, USA, Zwitserland
Amiklin	Frankrijk, Turkije
Amikosit	Roemenië, Tunisie, Turkije
Amikram	Peru
Amukin	België, Luxemburg, Nederland
Apalin	Maleisië
Baxi K	Chili, Mexico
Behcacin	Indië, Venezuela
Belka	Indië
Biclin	Duitsland, Finland, Mexico, Oostenrijk, Portugal, Spanje, Zweden
Biodacyna	Polen
Biokacin	Mexico
Briklin	Griekenland
Cadicin	Indië
Chemacin	Italië
Cikabit	Indië
Cinamica	Indië
Cinas	Indië
Consumonit	Griekenland
Domak	Indië
Doxocar	Argentinië
Elcin	Indië
Elmik	Indië
Emcin	Indië
Emica	Indië
Farcyclin	Griekenland
Flexelite	Griekenland
Greini	Argentinië
Ipacin	Iran
Itukacin	Peru
Kancin	Griekenland
Lanomycin	Griekenland
Lukadin	Italië
Masmika	Indië
Mediamik	Italië
Micalpha	Griekenland
Micigen	Mexico
Migracin	Italië
Mikacin	Saudi-Arabië
Nekacin	Italië
Novamin	Brazilië
Orlobin	Griekenland
Remikin	Griekenland
Rovericlin	Griekenland
Uzix	Griekenland

Literatuur : Amikacin sulfate

	type	publicatie
3	Artikel	Trissel LA, Martinez JF. Compatibility of amifostine with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 2208-2212.
59	Artikel	Trissel LA, Gilbert DL, Martinez JF, Kim MC. Compatibility of remifentanil hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2192-2196.
73	Artikel	Lor E, Takagi J. Visual compatibility of foscarnet with other injectable drugs. Am J Hosp Pharm 1990 ; 47: 157-159.
84	Artikel	Trissel LA, Martinez JF. Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 495-499.
99	Artikel	Trissel LA, Martinez JF. Compatibility of aztreonam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
104	Artikel	Hall PD, Yui D, Lyons S, Bosso JA. Compatibility of filgrastim with selected antimicrobial drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 185-189.
132	Artikel	Najari Z, Rusho WJ. Compatibility of commonly used bone marrow transplant drugs during Y-site delivery. Am J Health-Syst Pharm 1997 ; 54: 181-184.
169	Artikel	Trissel LA, Martinez JF. Physical compatibility of melphalan with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1993 ; 50: 2359-2363.
182	Artikel	Trissel LA, Gilbert DL, Martinez JF. Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 56-60.
186	Artikel	Swart EL, Mooren RAG, Van Loenen AC. Compatibility of midazolam hydrochloride and lorazepam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 2020-2022.
198	Artikel	Gayed AA, Kheshary PR, Hinkle RL. Visual compatibility of diltiazem injection with various diluents and medications during simulated Y-site injection. Am J Health-Syst Pharm 1995 ; 52: 516-520.
244	Artikel	Trissel LA, Martinez JF. Compatibility of filgrastim with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1907-1913.
248	Artikel	Trissel LA, Martinez JF. Turbidimetric assessment of the compatibility of taxol with 42 other drugs during simulated Y-site injection. Am J Hosp Pharm 1993 ; 50: 300-304.
249	Artikel	Trissel LA, Martinez JF. Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
253	Artikel	Trissel LA, Chandler SW, Folstad JT. Visual compatibility of amsacrine with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1990 ; 47: 2525-2528.
256	Artikel	Inagaki K, Takagi J, Lor E, Lee KJ, Nii L, Gill MA. Stability of fluconazole in commonly used intravenous antibiotic solutions. Am J Hosp Pharm 1993 ; 50: 1206-1208.
280	Artikel	Allen LV, Stiles ML, Prince SJ, Sylvestri MF. Stability of cefpirome sulfate in the presence of commonly used intensive care drugs during simulated Y-site injection. Am J Health-Syst Pharm 1995 ; 52: 2427-2433.
285	Artikel	Elmore RL, Contois ME, Kelly J, Noe A, Poirier A. Stability and compatibility of admixtures of intravenous ciprofloxacin and selected drugs. Clin Ther 1996 ; 18: 246-255.
299	Artikel	Trissel LA, Martinez JF, Gilbert DL. Compatibility of cisatracurium besylate with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1735-1741.
300	Artikel	Trissel LA, Gilbert DL, Martinez JF. Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1287-1292.
301	Artikel	Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM. Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1295-1300.
307	Artikel	Trissel LA, Martinez JF. Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1792-1799.
316	Artikel	Veltri M, Lee CKK. Compatibility of neonatal parenteral nutrient solutions with selected intravenous drugs. Am J Health-Syst Pharm 1996 ; 53: 2611-2613.
334	Artikel	Trissel LA, Tramonte SM, Grilley BJ. Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 988-992.
335	Artikel	Trissel LA, Bready BB, Kwan JW, Santiago NM. Visual compatibility of sargramostim with selected antineoplasic agents, anti-infectives, or other drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 402-406.
336	Artikel	Forman JK, Lachs JR, Souney PF. Visual compatibility of acyclovir sodium with commonly used intravenous drugs during simulated Y-site injection. Am J Hosp Pharm 1987 ; 44: 1408-1409.
337	Artikel	Bashaw ED, Amantea MA, Minor JR, Galleli JF. Visual compatibility of zidovudine with other drugs during simulated Y-site administration. Am J Hosp Pharm 1988 ; 45: 2532-2533.
367	Artikel	Thompson DF, Allen LV, Desai SR, Rao PS. Compatibility of furosemide with aminoglycoside admixtures. Am J Hosp Pharm 1985 ; 42: 116-119.
384	Artikel	Colucci RD, Cobuzzi LE, Halpern NA. Visual compatibility of esmolol hydrochloride and various injectable drugs during simulated Y-site injection. Am J Hosp Pharm 1988 ; 45: 630-632.
385	Artikel	Benedict MK, Roche VF, Banakar UV, Hilleman DE. Visual compatibility of amiodarone hydrochloride with various antimicrobial agents during simulated Y-site injection. Am J Hosp Pharm 1988 ; 45: 1117-1118.
386	Artikel	Colucci RD, Cobuzzi LE, Halpern NA. Visual compatibility of labetalol hydrochloride injection with various injectable drugs during simulated Y-site injection. Am J Hosp Pharm 1988 ; 45: 1357-1358.
405	Artikel	Nieves-Cordero AL, Luciw HM, Souney PF. Compatibility of narcotic analgesic solutions with various antibiotics during simulated Y-site injection. Am J Hosp Pharm 1985 ; 42: 1108-1109.
434	Artikel	Goodwin SD, Nix DE, Heyd A, Wilton JH. Compatibility of ciprofloxacin injection with selected drugs and solutions. Am J Hosp Pharm 1991 ; 48: 2166-2171.
472	Artikel	Wohlford JG, Fowler MD. Visual compatibility of hetastarch with injectable critical-care drugs. Am J Hosp Pharm 1989 ; 46: 995-996.
491	Artikel	Turowski RC, Durthaler JM. Visual compatibility of idarubicin hydrochloride with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 2181-2184.
492	Artikel	Trissel LA, Parks NPT, Santiago NM. Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 2186-2189.
496	Artikel	Lor E, Sheybani T, Takagi J. Visual compatibility of fluconazole with commonly used injectable drugs during simulated Y-site administration. Am J Hosp Pharm 1991 ; 48: 744-746.
552	Artikel	Martinez JF, Trissel LA, Gilbert DL. Compatibility of warfarin sodium with selected drugs and large-volume parenteral solutions. Int J Pharm Compound 1997 ; 1: 356-358.
561	Artikel	Nunning BC, Granatek AP. Physical compatibility and chemical stability of amikacin sulfate in large-volume parenteral solutions. Part II. Current Ther Res 1976 ; 20: 359-368.
565	Artikel	Marble DA, Bosso JA, Townsend RJ. Compatibility of clindamycin phosphate with amikacin sulfate at room temperature and with gentamicin sulfate and tobramycin sulfate under frozen conditions. Drug Intell Clin Pharm 1986 ; 20: 960-963.
575	Artikel	Holmes CJ, Ausman RK, Kundsin RB, Walter CW. Effect of freezing and microwave thawing on the stability of six antibiotic admixtures in plastic bags. Am J Hosp Pharm 1982 ; 39: 104-108.
604	fabrikant	Stabilité des médicaments dans l'Intermate® SV50, 100, 200 Baxter 1998
639	Artikel	Zbrozek AS, Marble DA, Bosso JA, Bair JN, Townsend RJ. Compatibility and stability of clindamycin phosphate - aminoglycoside combinations within polypropylene syringes. Drug Intell Clin Pharm 1987 ; 21: 806-810.
673	Artikel	Bullock L, Clark JH, Fitzgerald JF, Glick MR, Hancock BG, Baenziger JC, Black CD. The stability of amikacin, gentamicin, and tobramycin in total nutrient admixtures. JPEN 1989 ; 13: 505-509.
905	Artikel	Trissel LA, Martinez JF. Screening teniposide for Y-site physical incompatibilities. Hosp Pharm 1994 ; 29: 1010-1017.
921	Artikel	Trissel LA, Gilbert DL, Martinez JF. Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration. Hosp Pharm 1998 ; 33: 284-292.
999	Artikel	Watson D. Piggyback compatibility of antibiotics with pediatric parenteral nutrition solution. JPEN 1985 ; 9: 220-224.
1022	Artikel	Hutchinson SMW. Heparin and aminoglycosides instability. Drug Intell Clin Pharm 1986 ; 20: 886.
1035	Artikel	Bisaillon S, Sarrazin R. Compatibility of several antibiotics or hydrocortisone when added to metronidazole solution for intravenous infusion. J Parenter Sci Technol 1983 ; 37: 129-132.
1047	Artikel	Souney PF, Colucci RD, Mariani G, Campbell D. Compatibility of magnesium sulfate solutions with various antibiotics during simulated Y-site injection. Am J Hosp Pharm 1984 ; 41: 323-324.
1057	Artikel	Cutie MR. Compatibility of verapamil hydrochloride injection with commonly used additives. Am J Hosp Pharm 1983 ; 40: 1205-1207.
1072	Artikel	Saltsmann CL, Tom CM, Mitchell A, Fan JH, Gailey RA. Compatibility of levofloxacin with 34 medications during simulated Y-site administration. Am J Health-Syst Pharm 1999 ; 56: 1458-1459.
1201	Artikel	Yuhas EM, Lofton FT, Rosenberg HA, Mayron D, Baldinus JG. Cimetidine hydrochloride compatibility III: Room temperature stability in drug admixtures. Am J Hosp Pharm 1981 ; 38: 1919-1922.
1315	Artikel	Halpern NA, Colucci RD, Alicea M, Greenstein R. Visual compatibility of enalaprilat with commonly used critical care medications during simulated Y-site injection. Int J Pharm Clin Pharmacol Ther Tox 1989 ; 27: 294-297.
1410	Artikel	Trissel LA, Martinez JF, Simmons M. Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 141-145.
1415	Artikel	Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M. Compatibility of medications with 3-in-1 parenteral nutrition admixtures. JPEN 1999 ; 23: 67-74.
1423	Artikel	Trissel LA, Martinez JF, Gilbert DL. Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 514-518.
1490	Artikel	Halpern NA, Colucci RD, Alicea M, Greenstein R. The compatibility of nicardipine hydrochloride injection with various ICU medications during simulated Y-site injection. Int J Pharm Clin Pharmacol Ther Tox 1989 ; 27: 250-254.
1625	Artikel	Trissel LA, Saenz C, Williams YW, Ingram D. Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2001 ; 5: 314-321.
1712	Artikel	Trissel LA, Saenz CA. Compatibility screening of Precedex during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 230-233.
1713	Artikel	Trissel LA, Saenz CA. Compatibility screening of bivalirudin during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 311-315.
1721	Artikel	Trissel LA, Williams KY, Baker MB. Compatibility screening of Hextend during simulated Y-site administration with other drugs. Int J Pharm Compound 2001 ; 5: 69-72.
1754	Artikel	Trissel LA, Gilbert DL, Wolkin AC. Compatibility of docetaxel with selected drugs during simulated Y-site administration. Int J Pharm Compound 1999 ; 3: 241-244.
1759	Artikel	Servais H, Tulkens PM. Stability and compatibility of ceftazidime administered by continuous infusion to intensive care patients. Antimicrob Agents Chemother 2001 ; 45: 2643-2647.
1800	Artikel	Voytilla KL, Tyler LS, Rusho WJ. Visual compatibility of azithromycin with 24 commonly used drugs during simulated Y-site delivery. Am J Health-Syst Pharm 2002 ; 59: 853-855.
1803	Artikel	Trissel, LA, Saenz CA, Ogundele OB, Ingram D, Baker MB. Compatibility of fenoldopam mesylate with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2003 ; 60: 80-85.
1816	Artikel	Zhang Y, Trissel LA. Stability of amikacin sulfate in autodose infusion system bags. Int J Pharm Compound 2003 ; 7, 3: 230-232.
1868	Artikel	Husson E, Crauste-Manciet S, Hadj-Salah E, ,Segier JC, Broissard D. Stabilité galénique de mélanges commercialisés de nutrition parentérale en présence de médicaments: médicaments dans le mélange. Nutr Clin Metab 2003 ; 17: 8-14.
1925	Artikel	Trissel LA , Williams KY, Gilbert DL. Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions. J Am Pharm Assoc 2000 ; 40: 515-519.
1953	Artikel	Trissel LA, Saenz CA, Ogundele AB, Ingram DS. Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2004 ; 61: 2289-2293.
1982	Artikel	Trissel LA, Ogundele AB. Compatibility of anidulafungin with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2005 ; 62: 834-837.
2090	Artikel	Pere H, Chasse V, Forest JM, Hildgen P. Compatibility of injectable pantoprazole in Y-site administration. Pharmactuel 2004 ; 37: 193-196.
2109	Artikel	Pelletier E, Forest JM, Hildgen P. Compatibilité de la kétamine injectable lors de l’administration en dérivé avec d’autres médicaments usuels. Pharmactuel 2006 ; 39: 71-75.
2141	Artikel	Barinian N, Chanteux H, Viaene E, Servais H, Tulkens PM. Stability and compatibility study of cefepime in comparaison with ceftazidime for potential administration by continuous infusion under conditions pertinent to ambulatory treatment of cystic fibrosis patients and to administration in intensive care units. J Antimicrob Chemother 2003 ; 51: 651-658.
2231	Artikel	de Jongh R, Hens R, Basma V, mouton JW, Tulkens PM, Carryn S. Continuous versus intermittent infusion of temocillin, a directed spectrum penicillin for intensive care patients with nosocomial pneumonia: stability, compatibility, population pharmacokinetic studies and breakpoint selection. J Antimicrob Chemother 2008 ; 61, 2: 382-388.
2247	Artikel	Chan P, Heatherly K, Kupiec T.C, Trissel L.A. Compatibility of caspofungin acetate injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2008 ; 12, 3: 276-278.
2262	Artikel	Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmor T, Schaufelberger D. Compatibility of doripenem with other drugs during simulated Y-site administratioN Am J Health-Syst Pharm 2008 ; 65: 1261-1265.
2269	Artikel	Chan P, Bishop A, Kupiec TC, Trissel LA, Gole D, Jimidar IM, Vermeersch H. Compatibility of ceftobiprole medocaril with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2008 ; 65, 16: 1545-1551.
2296	fabrikant	Témocilline (Negaban®) - Résumé des caractéristiques du produit Eumedica 2017
3012	Artikel	Sullivan T, Forrest J.M, Leclair G. Compatibility of Cloxacillin Sodium with Selected Intravenous Drugs During Simulated Y-Site Administration Hosp Pharm 2015 ; 50, 3: 214-220.
3216	Artikel	Legris ME, Valiquette ME, Lavoie A, Forest JM, Leclair G. Compatibilité physique par évaluation visuelle du salbutamol injectable lors de son administration en Y. Pharmactuel 2011 ; 44, 1 : 14-18
3249	Artikel	Singh BM, Dedhiya MG, Dinunzio J, Chan P, Kupiec TC, Trissel LA, Laudano JB. Compatibility of ceftaroline fosamil for injection with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2011 ; 68: 2163-2169.
3332	fabrikant	Tigecycline (Tigacyl®) - Summary of Product characteristics Pfizer 2012
3385	Artikel	Raverdi V, Ampe E, Hecq JD, Tulkens PM. Stability and compatibility of vancomycin for administration by continuous infusion. J Antimicrob Chemother 2013 ; 68: 1179-1182.
3408	Artikel	Tollec S, Touzin K, Pelletier E, Forest J.M. Evaluation visuelle de la compatibilité physique de la naloxone avec d’autres médicaments intraveineux usuels. Pharmactuel 2013 ; 46, 1 : 16-21.
3522	fabrikant	Flucloxacillin - Summary of Product Characteristics. Actavis 2013
3523	fabrikant	Ceftriaxone (Rocephin®) - Summary of Product Characteristics. Roche 2018
3526	fabrikant	Clindamycin (Dalacin®) - Summary of Product Characteristics Pharmacia 2010
3527	fabrikant	Amoxicillin (Amoxil®) – Summary of Product Characteristics Glaxo Smith Kline 2018
3540	fabrikant	Heparin sodium - Summary of Product Characteristics. Wockhardt 2010
3543	fabrikant	Ceftazidime – Summary of Product Characteristics Wockhardt 2013
3544	fabrikant	Cefoperazone (Cefobid®) - Summary of Product Characteristics Pfizer 2006
3545	fabrikant	Amoxicilline / acide clavulanique - Résumé des caractéristiques du produit Mylan SAS 2009
3546	fabrikant	Cefamandole Flavelab - Résumé des caractéristiques du produit Panpharma SA 2007
3548	fabrikant	Cefepime (Maxipime®) - Summary of Product caracteristics. Bristol Myers Squibb 2007
3549	fabrikant	Amikacine B Braun - Résumé des caractéristiques du produit. B Braun 2012
3578	fabrikant	Cisplatin - Summary of Product Characteristics Accord Healthcare 2011
3586	fabrikant	Piperacilline tazobactam Actavis® - Résumé des caractéristiques du produit Actavis France 2010
3587	fabrikant	Ticarcilline/acide clavulanique (Timentin®) - Summary of Product Characteristics GlaxoSmithKline 2014
3594	fabrikant	Metronidazole (Flagyl®) - Summary of Product Characteristics Zentiva 2013
3644	fabrikant	Calcium gluconate® - Summary of Product Characteristics Hameln Pharmaceuticals 2010
3656	fabrikant	Teicoplanine (Targocid®) - Résumé des caractéristiques du produit Sanofi Aventis France 2014
3674	fabrikant	Erythromycin lactobionate - Summary of Product Characteristics PanPharma 2016
3677	fabrikant	Cefpirome (Cefrom®) - Résumé des caractéristiques du produit Sanofi Aventis France 2008
3687	fabrikant	Cefuroxime sodium - Summary of Product Characteristics Stravencon 2013
3728	Artikel	Correard F, Savry A, Gauthier-Villano L, Pisano P, Pourroy B. Visual compatibility of defibrotide with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2014 ; 71: 1288-1291.
3766	Artikel	Forrest J.M, Hildgen P. Compatibilité de l’acétylcystéine injectable lors de son administration en Y avec d’autres médicaments usuels Pharmactuel 2014 ; 47, 3 : 161-165.
3767	Artikel	Legris M.E, Lavoie A, Forrest J.M, Hildgen P. Compatibilité par évaluation visuelle du thiopental injectable lors de son administration en Y avec des médicaments usuels. Pharmactuel 2014 ; 47, 3 : 167-172.
3791	Poster	Sadou Yaye H, Burtet E, Hamel C, Aljhni R, Gard C, Tilleul P. Étude de la compatibilité physico-chimique du phloroglucinol injectable durant les mélanges au sein des tubulures en Y. Apifh Congress, Paris November 2014 2014
3824	Artikel	Boudi S, Roy H, Forest JM, Leclair G. Compatibilité physique de l'association amoxicilline-acide clavulanique en injection avec plusieurs autres médicaments lors d'une administration en Y. Pharmactuel 2023 2023;56,3:91-98
3827	Poster	Ghazi I.M, Hamada Y, Nicolau D.P. Compatibility of tedizolid phosphate with selected intravenous drugs via simulated Y-site conditions. ASHP Midyear 2015
3828	Poster	Thabit A.K, Hamada Y, Nicolau D.P. Ceftozolane/tazobactam physical compatibility during simulated Y-site administration. ASHP Midyear 2015
3829	Poster	So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L. Compatibility of isavunazonium sulfate during simulated Y-site administration. ASHP Midyear 2015
3883	fabrikant	Ceftazidime - Résumé des caractéristiques du produit Arrow 2016
3964	Artikel	Audet M.A, Forest E, Friciu M, Forest J.M, Leclair G. Compatibilité du citrate de caféine injectable avec plusieurs autres médicaments. Pharmactuel 2017 ; 50,1 : 27-33.
4055	Artikel	Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D. Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 , 75, 1:36-44
4319	Artikel	Lessard J-J, Caron E, Schérer H, Forest J-M, Leclair G. Compatibility of Y-site Injection of Meropenem Trihydrate With 101 Other Injectable Drugs. Hosp Pharm 2020 ; 55, 5: 332-337.
4354	Poster	Sicard G, Donnette M, Martin N, Gensollen S, Pourroy B, Fanciullino R. Compatibilité visuelle du Vyxeos lors d'administration en Y avec une sélection de médicaments injectables. GERPAC Congress 2019 2019
4380	fabrikant	Posaconazole (Noxafil®) - Summary of Product Characteristics Merck Sharp & Dohme Limited 2019
4389	Artikel	Côté K, Correal F, Metras M.E, Friciu M, Forest J.M, Leclair G. Compatibilité physique des médicaments administrés en Y aux soins intensifs, en particulier la dexmédétomidine, le lévosimendan et la kétamine. Pharmactuel 2019 ;52,4:206-213
4419	Artikel	Holt R.J, Siegert S.W.K, Krishna A. Physical Compatibility of Ibuprofen Lysine Injection with Selected Drugs During Simulated Y-site Injection. J Pediatr Pharmacol Ther 2008 ; 13, 3: 155-161.
4524	Poster	Stucki C, Sautter A-M, Bonnabry P. Physical compatibility of the propofol emulsion with 33 drugs used in anaesthesiology. ESCP Symposium, Geneva, Switzerland 2009
4528	Artikel	Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N. Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration. Int J Pharm Compound 2021 ;25,1:52-61
4603	Artikel	Vallée M, Barthélémy I, Friciu M, Pelletier E, Forest J.M, Benoit F, Leclair G. Compatibility of Lactated Ringer’s Injection With 94 Selected Intravenous Drugs During Simulated Y-site Administration. Hosp Pharm 2021 ; 56, 4: 228-234.
4650	fabrikant	Ceftobiprole (Zevtera 500 mg powder for concentrate for solution for infusion.) Summary of Product Characteristics, Advanz Pharma updated 4 aug 2021. Advanz Pharma 2021
4654	Poster	Sicard G, Donnette M, Martin N, Gensollen S, Pourroy B, Fanciullino R. Compatibilité visuelle du Vyxeos® lors d'administration en Y avec une sélection de médicaments injectables. Communication personnelle 2021
4742	Artikel	Macoviciuc M, Nguyen C, Forest J-M, Leclair G. Compatibilité physique de l’acétaminophène injectable avec 102 autres médicaments lors d’une administration en Y. Pharmactuel 2022 ; 55, 4: 247-255.
4801	Artikel	Ruiz V, Yuwei Shen Y, Abouelhassan Y, Fouad A, Nicolau D, Kuti J. Physical compatibility of sulbactam/durlobactam with select intravenous drugs during simulated Y-site administration. Am J Health-Syst Pharm 2024 ;51,1:

Mentions Légales